Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
EMA raises concerns about deaths in Oxbryta trials
Shares of Agios and Fulcrum rise after Pfizer's decision
By Kashish Tandon and Christy Santhosh
Sept 26 (Reuters) -Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further trials to confirm the benefits.
In July, the European Medicines Agency posted online concerns about deaths in two of those trials. The regulator, after a meeting on Thursday to discuss the data, said that it had serious concerns about the safety. It recommended an immediate suspension of its authorization.
At least three Wall Street brokerages said the withdrawal could create an immediate need to accelerate trials of rival drugs for the inherited condition, including Agios Pharmaceuticals' AGIO.O mitapivat and Fulcrum Therapeutics' FULC.O pociredir.
Enrollment in an early-stage trial has been a hurdle for Fulcrum, said analysts at Leerink.
In case of Agios, it could create pressure on regulators to speed up the review, Piper Sandler analysts said.
If mitapivat shows benefit in reducing the painful episodes that mark the disease, "we anticipate this will enable an easier regulatory review, especially now considering the greater demands from patients who can no longer access Oxbryta," said Piper Sandler's Christopher J. Raymond.
Shares of Agios rose 4% while Fulcrum jumped more than 20% in early trading.
Two recently approved gene therapies - bluebird bio's BLUE.O Lyfgenia and Vertex Pharmaceuticals' VRTX.O and partner CRISPR Therapeutics' CRSP.BN Casgevy - are reserved for people with severe form of the disease.
The removal of Oxbryta likely leaves the vast majority of patients, who have mild-moderate symptoms, relying on chemotherapy medicine hydroxyurea, said Stifel analyst Dae Gon Ha on Thursday.
Sickle cell disease affects an estimated 100,000 people in the U.S., most of whom are Black.
The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla. Investors have punished the company as it navigates sharply dropping sales for its COVID vaccines and drugs, a weaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and disappointing clinical data for an obesity pill it was developing.
Pfizer's shares were marginally down on Thursday. The stock is trading at around half its pandemic highs.
Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. It also picked up two other experimental sickle cell treatments, both of which remain in clinical trials, according to Pfizer's website.
In patients with the disease, red blood cells become sickle or crescent shaped and can cause strokes, organ damage and early death, as well as debilitating pain crises.
Reporting by Christy Santhosh and Kashish Tandon in Bengaluru; Additional reporting by Michael Erman in New Jersey; Editing by Sriraj Kalluvila
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
